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Synthetic triterpenoids including CDDO, its methyl ester (CDDO-Me, bardoxolone methyl), 
and its imidazolide (CDDO-Im) enhance Nrf2-mediated anti-oxidant and anti-inflammatory 
activity in many diseases by reacting with thiols on the adaptor protein, Keap1. Unlike 
monofunctional CDDO-Me, the bifunctional analog, CDDO-Im, has a second reactive site 
(imidazolide) and can covalently bind to amino acids other than cysteine on target proteins 
such as glutathione S-transferase pi (GSTP), serum albumin, or Keap1. Here we show for the 
first time that bifunctional CDDO-Im (in contrast to CDDO-Me), as low as 50 nM, can 
covalently transacylate arginine and serine residues in GSTP and cross link them to adjacent 
cysteine residues. Moreover, we show that CDDO-Im binds covalently to Keap1, by forming 
permanent Michael adducts with 8 different cysteines, and acyl adducts with lysine and 
several tyrosine residues. Modeling studies suggest the Tyr 85 adduct stabilizes the Keap1-
Cul3 complex, thereby enhancing the potency of CDDO-Im.   
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Synthetic oleanane triterpenoids such as 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid 
(CDDO) derivatives are multifunctional electrophilic agents that have been used to prevent 
and treat many chronic diseases in both in vitro and in vivo models1-4. The methyl ester 
derivative (CDDO-Me) has undergone clinical trials for the treatment of cancer, pulmonary 
disease, and chronic kidney disease5. The , unsaturated ketones in the A and C rings of 
CDDO derivatives are considered to be essential for their pharmacological action. It has been 
hypothesized that covalent binding to key cysteine residues on proteins through Michael 
addition disrupts protein-protein interaction, leading to a pharmacological response1, 2, 6, 7. 
Both CDDO-Me and CDDO-Imidazolide (CDDO-Im) can form covalent adducts at C1 of the 
A ring with cysteine residues in proteins through reversible Michael addition thio-alkylation 
(Figure 1 and Scheme 1)6, 8. Many cellular signalling proteins such as I-kappa-B-kinase 
(IKK), estrogen receptors (ER), insulin signalling proteins, and janus kinase/signal 
transducers and activators of transcription (JAK/STAT) have been identified as targets for 
CDDO-Im in cell cultures1, 9.
One of the primary targets of triterpenoids is the Nrf2-Keap1 pathway, one of the most 
important cellular protective mechanisms against chemical/oxidative stresses2. Keap1, a 
cysteine-rich adaptor protein, contains an N-terminal Broad complex, Tram- track, and Bric-
a-brac (BTB) domain, a central intervening region (IVR), and a Kelch domain close to the C-
terminus (Figure 2A). Keap1 interacts with Nrf2 through binding of its C-terminal Kelch 
domain to two distinct degron motifs (DLG and ETGE degron) present in the Neh2 domain 
of Nrf2 (Figure 2B)10, 11. Under normal physiological conditions, Keap1 maintains low levels 
of Nrf2 by promoting its Cul3-Rbx1-mediated ubiquitination and subsequent proteasomal 
degradation. Under conditions of cellular stress, reactive species modify sensor cysteine 
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residues within Keap1 and block the degradation of Nrf2, leading to cellular accumulation of 
Nrf2, which subsequently promotes cytoprotective genes (Figure 2C). Several potential 
models have been proposed to explain how covalent modification of cysteine residues in 
Keap1 activates the Nrf2 pathway12. In the “hinge and latch” model (Figure 2D), covalent 
modification of key cysteine residues such as Cys151, Cys273, and Cys288 in the BTB and 
IVR domains of Keap1 lead to conformational changes, thus disrupting the interaction 
between Nrf2 and Kelch13. Alternatively, in the Cul3-dissociation model (Figure 2E), 
covalent modification of cysteine residues in the BTB domain decreases the binding of Cul3 
to Keap1, leading to the loss of Nrf2 ubiquitination. In particular, modification of Cys151 
that is in close proximity to the Cul3 binding interface, is consistent with this Cul3-
dissociation model14. 
The triterpenoid CDDO-Im was designed to be a bifunctional drug, in contrast to the 
monofunctional molecule, CDDO-Me, in which only the A ring of oleanolic acid has been 
activated.  Thus, the imidazolide moiety attached to carbonyl C-28 of CDDO-Im confers 
much greater potential for irreversible acylation of nucleophilic amino acid residues on 
proteins, compared to the less reactive methyl ester moiety of CDDO-Me (Scheme 1). 
Indeed, CDDO-Im has been found to have several biological activities not shared with 
CDDO-Me 1, 15, and in some instances, though not all 6, 16, CDDO-Im is significantly more 
potent than CDDO-Me. In almost every case examined, CDDO-Im is also much more potent 
than CDDO-free acid.  The greater potency of CDDO-Im is particularly striking in the 
suppression of macrophage production of inducible nitric oxide synthase17, which is an Nrf2-
dependent gene17, 18. Thus, in primary macrophage cultures, CDDO-Im is more than 1,000-
fold more potent than CDDO-Me or CDDO-free acid in such assays7, 18. This greater activity 
of CDDO-Im is also seen in assays for the induction of another Nrf2-dependent gene, heme 
oxygenase (HO-1), in which the imidazolide is markedly more potent than the methyl ester or 
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the free acid in enhancing both HO-1 gene and protein expression in several different cell 
types15, 19. Induction of HO-1 by CDDO-Im is almost completely abolished in Nrf2-knockout 
cells, compared to wild type19. Therefore, we hypothesized that additional molecular 
interactions between CDDO-Im and other amino acid residues in addition to cysteine could 
likely contribute to their potency and target selectivity. Thus, the aim of this study was to 1) 
investigate the binding of CDDO-Im to proteins using mass spectrometric methods and 2) 
explore its reactivity with Keap1 and its implication in the activation of Nrf2. 
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Characterization of CDDO-Im Modified-GSTP In Vitro. To characterise the Michael adducts 
of CDDO-Im, human glutathione S-transferase pi (GSTP) was chosen as a model as it contains 
several reactive cysteine residues. His-GSTP captured on nickel beads was exposed to a range 
of concentrations of CDDO-Im (50 nM-10 µM). LC-MS/MS analysis of the tryptic digests of 
CDDO-Im treated GSTP revealed multiple types of adducts, including a simple Michael adduct 
formed by thio-alkylation with cysteine, a cross-linked adduct, and an acylation adduct formed 
with arginine residues (Table 1). Michael addition of cysteine in GSTP to CDDO-Im followed 
by the hydrolysis of the imidazolide amide bond resulted in adducts with a mass addition of 
491.3 amu. Figure 3A shows a representative MS/MS spectrum for a doubly charged ion at 
m/z 785.986, corresponding to the tryptic peptide 45ASCLYGQLPK54 with an additional mass 
of 491.3 amu. The peptide sequence was confirmed by partial singly charged y and b series 
ions. The modification site was confirmed by the presence of b3* (m/z 753.57), b4* (m/z 
866.64), and b8*(m/z 1328.02), all with adduction of 491.3 amu. The presence of a fragment 
ion of m/z 464.45 and 447.42 that was derived from CDDO carboxylic acid provided further 
evidence of the modification. This adduct was only detected on Cys47; no other sites were 
identified.
Cross-linked adducts are anticipated due to the presence of the bifunctional groups on CDDO-
Im. An abundant doubly charged ion at m/z 776.989 was detected, corresponding to the tryptic 
peptide 45ASCLYGQLPK54 with an additional mass of 473.3 amu. The cross-linked adduct 
could be formed by reaction of CDDO-Im with Cys47 and the adjacent serine residue in the 
sequence 45ASCLYGQLPK54. A typical MS/MS spectrum representing the tryptic peptide 
45ASCLYGQLPK54 with a mass addition of 473.3 amu is shown in Figure 3B. The peptide 
sequence was confirmed by a series of y product ions, and the cross-linked was evidenced by 
the presence of b2*(m/z 632.56, Ser46) and y8* (m/z 1395.29, Cys47), both with a mass 
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increment of 473.3 amu. The cross-linked adducts were also detected on multiple sites 
including Arg13-Cys14 and Arg100-Cys101 (Table 1). Similar to the modifications observed 
with S46, a stable adduct derived from an arginine residue was also detected (Figure S1, 
Arg186, 183LSARPK188) when a high concentration of CDDO-Im was used (500 µM). 
Covalent binding of CDDO-Im to GSTP was concentration-dependent (Figure 3C and 3D) 
with adducts being detectable at the lowest concentration of CDDO-Im (50 nM).  CDDO-Me 
did not form adducts with GSTP, except at very high concentrations (500 µM). The cross-
linked adducts appeared to be the major adducts formed between CDDO-Im and GSTP, 
probably due to the adduct stabilization through acylation at C28.
Characterization of HSA Modified by CDDO-Im In Vitro. Human serum albumin (HSA) has 
long been known to exhibit great affinity for many ligands and act as an endogenous target 
and/or quencher for numerous electrophilic compounds such as penicillins, α,β-unsaturated 
aldehydes, and acyl glucuronides 20-23. Adducts could be formed in HSA with various 
nucleophilic amino acid residues including lysine, cysteine, and histidine. To probe the 
chemical basis of the putative Michael and acylation adducts of CDDO-Im with HSA, HSA 
was incubated with CDDO-Im at various concentrations and time points. LC-MS/MS analysis 
of the tryptic digests revealed 23 CDDO-Im modified peptides, including peptides containing 
lysine (n=10), arginine (n=2), serine (n=7) or tyrosine (n=5) residues after incubation at the 
highest concentration of CDDO-Im (1 mM) (Supplementary Table 1). At lower concentrations, 
CDDO-Im appeared to bind selectively to lysine and tyrosine residues and some adducts could 
be detected at concentrations as low as 10 nM (Table 2).
A typical MS/MS spectrum representing the tryptic peptide 411YTK*K414 with a mass addition 
of 473.3 amu is shown in Figure 4A. A missed cleavage at the proposed site of covalent binding 
and the presence of y2* (m/z 748.4) and y3* (m/z 849.69) ions provided firm evidence of 
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acylation at Lys413. Similar to the modifications observed with lysine, stable adducts derived 
from tyrosine (Figure 4B) were also detected on multiple sites (Table 2). A semi-quantitative 
analysis of modification at each site revealed a concentration- and time-dependent increase for 
each modified peptide (Figure 4C & 4D). 
Characterization of CDDO-Im Modified Keap1 In Vitro. LC-MS/MS analysis of the tryptic 
digests of CDDO-Im-treated recombinant Keap1 protein also revealed multiple types of stable 
adducts, including a Michael adduct formed with cysteine and acylation adducts formed with 
tyrosine and lysine (Table 3). A representative MS/MS spectrum shows the peptide 
85YQDAPAAQFMAHK96 modified by CDDO-Im at Tyr85 (Figure 5A). The presence of 
adducted a1 ion (m/z 609.37) provided firm evidence of acylation at Tyr85. Multiple cysteine 
residues in Keap1 including Cys13, Cys14, Cys38, Cys257, Cys288, Cys489, Cys513, and 
Cys613, were modified by CDDO-Im, all with a mass addition of 473.3 amu. The mass addition 
of 473.3 amu could correspond to either a thioester adduct or a Michael adduct followed by 
acylation of the N-terminal amino group of isolated peptides. The absolute structure of these 
adducts requires further investigation. 
A concentration dependent increase of modification was observed at most sites except for 
Tyr85 (Figure 5B). Tyr85 appeared to be the major modification site when incubated with 
CDDO-Im at low concentration (100 nM); more sites were bound when the concentrations of 
CDDO-Im increased (Figure 5B and 5C). Both Cys151 and Tyr85 are located in a groove 
formed by the side chains of His 154, His 129 (Figure S2A), it is therefore not surprising that 
Tyr85 is readily modified by CDDO-Im. Covalent docking of CDDO-Im with Tyr85 
demonstrated that the ring system positioned away from Cys151, with the E ring occupying a 
small cavity near the side chain of His154 (Figure 5D).  Two hydrogen bonds are formed, one 
is between the backbone amide nitrogen of Met161 and the nitrile nitrogen of CDDO-Im 
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(rN...N = 2.96 ); another is formed between the backbone oxygen of Gly128 and the enolic Å
oxygen of the C-ring (rO...O =3 ) (Figure 5E). Surprisingly, modification of Cys151 by Å
CDDO-Im was not detected in this study. However, Cleasby et al. have shown that when 
CDDO-free acid covalently bound to Cys151, the ring systems positioned in the groove, and 
the C-4 gem-dimethyl group occupying a small cavity near the side chain of Val 155 and the 
hydrophobic portion of Lys 131 (Figure S2B)14. The close proximity of Tyr85 to the carbonyl 
carbon of CDDO-Im (5.7 ) and its flexible location makes it theoretically possible to form a Å
cross-linked adduct (Figure S2B). The difficulty to identify such a cross-linked adduct by 
searching algorithm may explain why Cys151 modification was not detected. 
Notably, we could not detect any adducts of CDDO-Me with Keap1, even when incubated at 
concentrations as high as 10 µM. This result again emphasizes the difference between 
CDDO-Im and CDDO-Me and the importance of the imidazolide moiety for irreversible 
covalent binding. 
Modification of Keap1 by CDDO-Im stabilizes the Keap1-Cul3 complex. To explore the 
impact of CDDO-Im modified Tyr85 on the Keap1-Cul3 complex formation, covalent 
docking of CDDO-Im with Tyr85 was performed using the crystal structure of the Keap1-
Cul3 complex (PDB code: 5NLB).  As shown in the crystal structure of the Keap1-Clu3 
complex, Tyr85 was identified as a key amino acid interacting with the Cul3 N terminal 
domain (Figure 6A). Covalent binding of CDDO-Im to Tyr85 positions the ring system 
towards Cul3, forming a bridge between the Keap1 and Cul3 (Figure 6B and C). Three 
hydrogen bonds could be potentially formed between the nitrile nitrogen of CDDO and the 
guanidinium nitrogen of Arg188 in Cul3 (rN...N = 1.9 , 3.2 , and 3.6 ) (Figure 6D). Å Å Å
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Although many electrophiles have been reported to enhance transcriptional activity of Nrf2 
through covalent modifications of cysteine thiols of Keap1, the detailed mechanisms by 
which these species affect the activity of Keap1 remain controversial12. Multiple mechanisms 
have been proposed including Keap1 conformation changes (“hinge and latch” model and 
Cul3-dissociation model) and increased Keap1 ubiquitination (ubiquitination switching 
model) owing to covalent modifications of multiple cysteine residues, all leading to 
disruption of Keap1-Nrf2 interaction and subsequent Nrf2 degradation12, 13, 24, 25. So far, 
cysteine residues in Keap1 have been identified as the only targets. Here we have 
demonstrated CDDO-Im, in contrast to CDDO-Me, covalently binds to amino acid residues 
other than cysteine through multiple chemical mechanisms. In particular, selective binding to 
Tyr85 in the BTB domain of human Keap1 protein may contribute to the greater potency of 
CDDO-Im to activate Nrf2 in certain contexts. 
As a bifunctional triterpenoid, CDDO-Im has the potential to form not only thio-alkyl adducts 
with cysteine residues in proteins as initial studies demonstrated6-8, but also acylation adducts 
with other nucleophilic amino acid residues such as lysine, arginine, serine, and tyrosine due 
to the presence of its reactive imidazolide group.  More importantly, intra and inter cross-
linked adducts can also be formed (Scheme 1). Among the 27 cysteine residues in human 
Keap1, 8 cysteine residues were modified by CDDO-Im, among which five (Cys257, 
Cys288, Cys489, Cys513, and Cys613) were the most readily modified by other electrophilic 
reagents26, 27 28. Cys273 and Cys288 are essential for Keap1 to control Nrf2 under both basal 
and stress conditions, whereas Cys151, located in a positively charged pocket, is identified as 
a primary target for many electrophiles under conditions of stress14, 25, 26, 29. Surprisingly, we 
did not detect CDDO-Im modified Cys151, although different forms of unmodified Cys151 
containing peptide (CVLHVMNGAVMYQIDSVVR) were detected, in agreement with other 
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observations 30(Figure S1B and C). Failure to detect Cys151 modification could be due to the 
hydrophobicity of the peptide or potential cross-linked adducts that cannot be identified by 
software. 
Modification of cysteine residues within the BTB and IVR domain (Cys151, Cys273 and 
Cys288) is postulated to alter the conformation of Keap1, which can either directly disrupt 
the interaction between Nrf2 and Kelch (“hinge and latch model) or block the ubiquitination 
of Nrf2 (Cul3-dissociation model), leading to Nrf2 nuclear accumulation31. However, the 
direct disruption of Keap1-Nrf2 interaction caused by a cysteine modification has been 
controversial. For example, Cys151 is remote from the Nrf2 substrate-binding domain, hence 
the conformation changes caused by modification of Cys151 may be unlikely to disrupt the 
Keap-Nrf2 complex 31. Even though Cys489 and Cys513 are located within the Kelch domain 
that directly binds to Nrf2, covalent binding of CDDO-Im to either cysteine residue seems 
unlikely to cause any disruptions as shown in the computational modelling studies (Figure 
S3). On the other hand, Cys151 modification was also postulated to cause alteration of the 
interface between BTB and Cul314, leading to down regulation of Nrf2 ubiquitination and 
subsequent proteasomal degradation. However, studies have shown that cysteine 
modifications by many Nrf2-inducing chemicals do not dissociate Keap1 from Cul332-34. Two 
possible hypotheses have been proposed to explain the down regulation of Nrf2 
ubiquitination caused by modification of critical cysteine residues in Keap1. One suggested 
that cysteine residues within BTB and IVR domains could form thioester conjugates with 
ubiquitin to accomplish ubiquitin transfer from Cul3 to the lysine residues in Nrf2; 
modification of critical cysteine residues which are selective to different electrophiles 
(“cysteine code”) thereby inhibits Keap1-dependent ubiquitination12, 24, 35. Alternatively, 
cysteine modifications might cause the switch of ubiquitination from Nrf2 to Keap1, leading 
to upregulation of Keap1 ubiquitination as well as Nrf2 nuclear accumulation31.
Page 11 of 31
ACS Paragon Plus Environment






























































Most importantly, we demonstrated for the first time that CDDO-Im selectively targets Tyr85 
in Keap1. Located at the entrance of a groove formed by the side chains of His154, His 129, 
and Cys15114, Tyr85 may adjust its position in response to interaction with particular ligands 
and this flexibility may play an important role in the formation of Keap1-Cul3 complex. 
Computational docking demonstrated that covalent binding of CDDO-Im to Tyr85 positions 
the CDDO ring system towards the Keap1-Cul3 binding interface. Three hydrogen bonds 
were formed between the CDDO nitrile nitrogen and Cul3 Arg188, which stabilise the 
Keap1-Cul3 complex rather than weaken or abrogate the complex formation as proposed 
previously34. The strong interaction between Keap1 and Cul3 was proposed to prevent Nrf2 
binding to the complex for ubiquitination36, 37. This is in contrast with the observation that 
only CDDO-Im exceptionally reduces the interaction between Keap1 and Cul3, although this 
only occurred at high concentrations of CDDO-Im (6 or 18 M of CDDO-Im)29, 34. It is 
important to note that CDDO-Im does not selectively bind to Tyr85 at these concentrations, 
indicating multiple mechanisms may contribute to the disruption of Keap1-Cul3 complex 
formation. In particular, cross-linked adducts formed at high concentrations of CDDO-Im 
may likely cause its unique function of disrupting the Keap1-Cul3 interaction. Thus, 
depending on the concentration, CDDO-Im may have significantly different functions1, 19.  
Selective modification of Tyr85 by CDDO-Im at low concentrations may have a pronounced 
effect on the stability of Keap-Cul3 complex, which may cause the switch of ubiquitination 
from Nrf2 to Keap1, leading to disruption of Keap1-Nrf2 interaction and increased self-
ubiquitination of Keap1. In contrast, modification of multiple cysteine residues and the 
formation of cross-linked adducts by CDDO-Im at high concentrations may cause large 
conformational changes in Keap1, leading to the dissociation of Nrf2 from Keap1.
It is important to emphasize that even within the same class of compounds, CDDO-Im and 
CDDO-Me can have different, sometimes opposite, effects on cellular functions. It has been 
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shown that there are major differences in the sets of genes, both Nrf2-dependent and Nrf23-
independent, upregulated or downregulated by either CDDO-Im or CDDO-Me15. It should 
also be noted that Nrf2 is not the only molecular target to which Keap1 binds. Significant 
direct interactions of Keap1 with the regulatory protein, p62, and the anti-oxidative protein, 
iASPP, have been reported 38, 39. In all of these situations, the context, especially the dose, of 
CDDO-Im will be a key determinant of any final biological response. A low dose of CDDO-
Im can give a certain response, and a higher dose an opposite effect1, 19, 40. The dose-
dependent covalent binding of CDDO-Im to many amino acid residues, which we have 
shown here, may account for some of these contextual variations.
In all situations, context is of critical importance. Thus it has been published that the action of 
CDDO-Im as an inducer of Nrf2 is “independent of the presence of Cys 151”  in Keap1 (Fig. 
7 in Tayaka et al., 2012)41, while the same group, using lower concentrations of CDDO-Im, 
later showed data indicating that this drug is “a Cys 151-preferring inducer” (Fig. 10 in Saito 
et al., 2016)42. Studies of interaction of triterpenoid molecules with Cys 151 have been 
performed both in silico and in cell cultures,  with many different agents, including CDDO, 
CDDO-Me, an epoxide of CDDO-Me, CDDO-Im, new analogs of CDDO-Im, and even 
tricyclic ene-one analogs which are not true triterpenoids43. Different concentrations of drug 
have been used in different studies, and even the context of Keap1 has sometimes been 
different. In some experiments Keap1 has been an intact whole molecule, but in others only 
the BTB domain of Keap1 has been used14. For all future studies it will be important to 
perform a complete dose-response evaluation. 
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   Conclusion
In summary, we have found that the bifunctional triterpenoid, CDDO-Im forms covalent 
adducts with many nucleophilic amino acids on important target proteins at concentrations as 
low as 10-50 nM, and can even form cross-links. The contrast with monofunctional CDDO-
Me is striking, since we could not detect adduct formation by CDDO-Me at concentrations 
less than 500 µM. Our data are directly relevant to known differences between CDDO-Im 
and CDDO-Me, although clearly these two molecules also share many common mechanisms 
of action.  Altogether our results highlight novel targets for bifunctional triterpenoids that 
may contribute to their important potency and activity. They provide new insights into the 
chemical mechanisms of action and pave the way for exploring potential novel cellular 
signaling pathways for bifunctional triterpenoids, including even newer pyridyl imidazolide 
derivatives44 that also form covalent acylation adducts, which will be described in a future 
publication. In all future work, it will be essential to consider context.    
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Chemicals. CDDO-Im was provided by Triterpenoid Therapeutics, Inc (USA). CDDO-Me and 
HSA (97-99% pure) were purchased from Sigma-Aldrich, trypsin from Promega (Madison, 
WI), liquid chromatography-mass spectrometry (LC-MS) grade solvents from Fisher Scientific 
UK Ltd (Loughborough, Leicestershire), and all other standard reagents from Sigma-Aldrich.
Concentration-Dependent Modification of HSA by CDDO-Im. CDDO-Im freshly 
dissolved in DMSO, followed by dilutions in phosphate buffer (10 mM, pH 7.4), was 
incubated with HSA (0.6 mM, 50 µL) in phosphate buffer in sealed Eppendorf tubes at 37 oC 
for 16 h. The molar ratios of drug to protein were 0.00001:1, 0.0001:1, 0.001:1, 0.01:1, 0.1:1, 
and 1:1. Protein was precipitated twice with 9 volumes of ice-cold methanol to remove free 
drug, and processed for LC-MS/MS analysis using previous methods45.  
Time-Dependent Modification of HSA by CDDO-Im. 10 µM CDDO-Im was incubated 
with HSA (0.6 mM, 300 µL) at 37 oC. Aliquots of 50 µL were removed after 10, 30, 60, and 
180 minutes and processed for LC-MS/MS analysis. 
Concentration-Dependent Modification of His-GSTP by triterpenoids. His-GSTP was 
expressed in E.coli as described previously22. Purified His-GSTP captured on nickel beads 
was incubated with a range of concentrations of CDDO-Im (50 nM-10µM) in phosphate 
buffer, pH 7.4 for 16 h. CDDO-Me (0.5 mM) was used as a positive control. The beads were 
then washed 5 times with 1000 µL phosphate buffer. The protein was subjected to on-bead 
tryptic digestion.  In brief, a suspension of beads in 30 µL of 50 mM ammonium bicarbonate 
buffer was incubated with 20 ng of trypsin for 16 h at 37 °C and the digests were analyzed by 
LC-MS/MS. 
Modification of Keap1 by CDDO-Im. Solutions of CDDO-Im, as described above, were 
incubated (0.1-10µM) with recombinant Keap1 protein46 at 37 oC for 16 h in phosphate 
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buffer (10 mM, pH 7.4). The mixture was then purified by 1D-gel electrophoresis using 
established protocol, followed by in gel-digestion45. The digests were further purified by 
C18-ziptiping and analyzed by LC-MS/MS.  
LC-MS/MS analysis of CDDO-Im protein adducts. The tryptic peptides were analyzed by 
a Triple TOF 5600 mass spectrometer (Sciex). Samples were reconstituted in 50 µL 0.1% 
formic acid and 2 µL of samples were delivered into the instrument using an Eksigent Nano-
LC system mounted with a nanoACQUITY UPLC Symmetry C18 Trap Column and an 
analytical BEH C18 nanoACQUITY Column (Waters, MA, USA). A NanoSpray III source 
was fitted with a 10 µm inner diameter PicoTip emitter (New Objective). Samples were 
loaded in 0.1% formic acid onto the trap, which was then washed with 2% ACN/0.1% FA for 
10 min at 2 µL/ min before switching in-line with the analytical column. A gradient of 
2−50% (v/v) ACN/0.1% (v/v) FA over 90 min was applied to the column at a flow rate of 
300 nL/min. Spectra were acquired automatically in positive ion mode using information-
dependent acquisition, using mass ranges of 400−1600 amu in MS and 100−1400 amu in 
MS/MS. Up to 25 MS/MS spectra were acquired per cycle (approximately 10 Hz) using a 
threshold of 100 counts per s, with dynamic exclusion for 12 s and rolling collision energy. 
Analysis of CDDO-Im modified proteins.  LC-MS/MS data were searched against the 
reviewed human proteome (UniProt/SwissProt accessed October 2018), using ProteinPilot 
software, v4.0 (Sciex). Data were refined using default parameters and searches performed 
with the following parameters: enzymatic cleavage restriction for trypsin, fixed modification- 
carbamidomethylation of cysteine; variable modifications-methionine oxidation (+15.99), 
asparagine and glutamine deamidation (+0.98); CDDO-Im modification of lysine, serine, 
tyrosine, and arginine (+473.3); CDDO-Im modification of cysteine (+473.3 or 491.3). 
Keap1 modelling. Crystal structures of BTB domain of human Keap1 (PDB code: 4CXI) and 
Keap1-Cul3 complex (PDB code: 5NBL) were used to generate models. GOLD 5.2 (CCDC 
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software) was used for covalent docking of CDDO-Im to Tyr85. To covalently link the 
CDDO-Im to Tyr85, the corresponding side chain was removed from the protein and the 
ligand modified to contain the side chain to allow flexibility. The site of covalent attachment 
was at the tyrosine Cα 30. A generic algorithm with ChemPLP as the fitness function was 
used to generate 10 binding modes per ligand. Default settings were retained for the “ligand 
flexibility”, “fitness and search options”, and “GA” settings.
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1 Cys14 GR*C*AALR 407.2529 473.3
2 Cys14 C*AALR 503.8094 473.3
3 Cys47 ASC*LYGQLPK 785.986 491.3
4 Cys47 AS*C*LYGQLPK 776.958 473.3
5 Cys101 DQQEAALVDMVNDGVEDLR*C*K 706.238 473.3
6 Arg186 LSAR*PK 572.9 473.3
1. CDDO-Im (50 nM-10 µM) was incubated with GSTP in phosphate buffer, pH 7.4 for 16 h.
2. The modified amino acid was labelled with *. 
Table 2. CDDO-Im modified HSA peptides detected in vitro1
CDDO-Im 
concentration (µM)
Entry Amino acid Peptide2 m/z
0.01 1 10 100
1 K137 K*YLYEIAR 764.94 √ √ √ √
2 Y138 KY*LYEIAR(Me) 771.9877 -- -- √ √
3 Y161 RY*K 470.3134 -- -- √ √
4 K162 YK*AAFTECCQAADK 1010.501 -- -- -- √
5 K199 LK*CASLQK 710.9803 -- -- -- √
6 K351 LAK*TYETTLEK 885.5318 -- -- -- √
7 Y353 TY*ETTLEK 729.3912 -- -- -- √
8 Y411 Y*TK 442.7766 -- -- -- √
9 K413 YTK*K 506.8359 -- -- -- √
10 K524 QIK*K 495.3375 -- -- -- √
11 K525 K*QTALVELVK 801.593 -- -- √ √
12 K541 ATK*EQLK 645.9232 -- -- -- √
1. CDDO-Im (10 nM-100 µM) was incubated with GSTP in phosphate buffer, pH 7.4 for 16 h.
2. The modified amino acid was labelled with *. 
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Table 3. CDDO-Im modified Keap1 peptides detected in vitro1
Entry Amino 
acid
Peptide sequence2 m/z Reported 
binding sites
















7 Tyr263 FY*VQALLR 742.4025 N
8 Cys288 C*EILQSDSR 762.4541 Y
9 Lys323 APK*VGR 550.864 N
10 Tyr443 Y*EPER 583.812 N
11 Cys489 LNSAEC*YYPER 909.4423 Y
12 Cys513 SGAGVC*VLHN 715.3806 Y
13 Cys613 SGVGVAVTMEPC*R 897.9634 Y
1. CDDO-Im (10 µM) was incubated with Keap1 in phosphate buffer, pH 7.4 for 16 h.
2. The modified amino acid was labelled with *.
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Supporting information
S1
A supplementary table and additional figures (Figure S1-S3) show the formation of CDDO-Im protein 
adducts and the interaction of CDDO-Im with Keap1. This material is available free of charge via the 
Internet at http://pubs.acs.org.
Amino acid Peptide2 m/z
Retention time 
(minutes)
K137 K*YLYEIAR 764.9434 82.06
K195 ASSAK*QR 610.8541 68.57
K199 LK*CASLQK 710.9154 74.6
K413 YTK*K 506.8073 72.22
K432 NLGK*VGSK 638.3876 77.25
K436 VTK*CCTESLVNR 628.3306 69.94
K524 QIK*K 495.3224 72.87
K525 K*QTALVELVK 801.4988 82.61
K536 HK*PK 491.812 66.39
K541 ATK*EQLK 645.8875 73.81
R142 LDELR*DEGK 516.6239 67.25
R222 LSQR*FPK 674.7512 80.01
S193 ASS*AK 468.7725 81.83
S202 CAS*LQK 561.8137 75.9
S220 LS*QR 488.796 72.97
S232 AEFAEVS*K 677.3669 79.01
S435 VGS*K 432.2647 73.52
S470 TPVS*DR 574.3217 71.09
S489 RPCFS*ALEVDETYVPK 776.4546 81.03
Y140 YLY*EIAR 700.8973 94.19
Y161 RY*K 470.2868 76.7
Y319 NY*AEAK 584.815 83.05
Y353 TY*ETTLEK 729.3921 85.8
Y411 Y*TK 442.2242 72.97
Table S1. CDDO-Im modified HSA peptides detected in vitro1
1. CDDO-Im (1mM ) was incubated with HSA in phosphate buffer, pH 7.4 for 16 h.









Figure S1. MS/MS spectra show (A) peptide LSARPK from GSTP was modified by CDDO-Im (500 µM) at 
Arg186 with a mass addition of 473.4 amu; GSTP was incubated with CDDO-Im (500!") in phosphate buffer 






Figure S2. The structure of Keap1 BTB domain. (A) Surface representation of the Keap1 BTB domain 
highlighting the location of Cys151 and Tyr85 (PDB 4CXI). (B) Cleasby et al have shown that CDDO 
carboxylate is covalently bound to Cys151(PDB 4CXI)1, the close proximity of carbonyl carbon to Tyr85 
(5.7A) suggests that a cross-linking adduct could be formed between Cys151 and Tyr85 if CDDO-Im is 
bound to Cys151 in a similar conformation. Images are illustrated by PyMOL (The PyMOL Molecular 








1. Cleasby, A.; Yon, J.; Day, P. J.; Richardson, C.; Tickle, I. J.; Williams, P. A.; Callahan, J. F.; Carr, R.; Concha, 
N.; Kerns, J. K.; Qi, H.; Sweitzer, T.; Ward, P.; Davies, T. G. Structure of the Btb Domain of Keap1 and Its 





Figure S3. The interaction between Nrf2 and keap1. (A) Crystal structure of Keap1- Kelch (yellow) and 
bound Nrf2 peptide (Cyan) Cul3(PDB code: 2FUL). (B) Covalent binding of CDDO-Im to cysteine residues in 
Kelch (modification of Cys489 is shown) is unlikely to affect the Nrf2 binding  as they are far away from the 
Nrf2 binding sites. Images are illustrated by PyMOL (The PyMOL Molecular Graphics System, Version 1.3 
Schrödinger, LLC.). 
S5
